Senti Biosciences is trading 10.09% up at $0.48 in pre-market after recovering from the August 20, 2026 regular-session decline, with the move appearing sector-driven rather than linked to a newly identified company-specific announcement.
- Recent coverage centers on the July 15 strategic transaction involving SENTI-202 and its Regulator Dial technology platform.
- Latest earnings coverage dates to August 14, 2026; broader pre-market futures are modestly higher. Trading activity and volume were unavailable; confidence is medium.